FDA Approves First Drug Comprised Of An Active Ingredient Derived From Marijuana To Treat Rare, Severe Forms Of Epilepsy

The U.S. Food & Drug Administration (FDA) recently approved Epidiolex oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two rare and severe forms of epilepsy. The approval marks the first ever drug comprised of an active ingredient derived from marijuana to be approved by the FDA.

In addition to being the first approved drug with an active ingredient derived from cannabis, the drug is also the first to be approved that is for the treatment of the aforementioned Dravet syndrome. According to statements from the FDA, the move signifies the FDA’s . . .